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Twenty-five isolates of Staphylococcus aureus, 24 isolates of Escherichia coli, and 25 isolates of Klebsiella
pneumoniae obtained from clinical material were tested in vitro forsusceptibility to cefamandole, tobramycin
and combinations ofthe two antibiotics utilizing an automated microdilution system. Synergistic or partially
synergistic bactericidal effects ofthe combination were observed against 15 ofthe S. aureus isolates (60%), 23
of the E. coli isolates (96%), and 19 ofthe K. pneumoniae isolates (76%) tested. Noantagonistic effects ofthe
combination were noted. This study suggests that cefamandole-tobramycin combinations are capable of
acting synergistically in vitro against certain gram-positive and gram-negative organisms and may have
potential usefulness in clinical situations such as gram-negative rod and staphylococcal sepsis.
INTRODUCTION
The enhanced or the diminished efficacy of certain antibiotic combinations com-
pared with single drugs in killing or inhibiting bacteria in vitro is now well recog-
nized. Controlled in vivo studies utilizing animal models of infection have demon-
strated that at least some combinations which are synergistic in vitro act
synergistically in vivo as well [1,2,12]. Furthermore, an appreciation ofthe kinetics of
synergy has enabled predictions of how different classes of antibiotics may interact
when combined. Thus, antibiotics which act at different sites in the bacterial cell, such
as cephalosporins and aminoglycosides, are often synergistic in combination. As new
antibiotics are developed, their interactions with other antibiotics are investigated to
anticipate how combinations may be used in eventual therapeutic strategies.
The present studies were undertaken to evaluate two relatively new antibiotics, cef-
amandole (7-D-mandelamido-3-[(1-methyl-IH-tetrazol-5-yl) thiomethyl] -3-cephem-
4-carboxylic acid as the sodium or lithium salt) and tobramycin (0-3-Amino-3-deoxy-
a-D-ribo-glucopyranosyl-(1-4)]-O-[2,6-diamino-2,3,6-trideoxy-a-D-ribo-hexopyran-
osyl-(1-6)]-2-deoxystreptamine) sulfate to determine their potential synergistic ac-
tivity in vitro against Staphylococcus aureus, Escherichia coli, and Klebsiellapneu-
moniae.
MATERIALS AND METHODS
Twenty-five strains of S. aureus, twenty-four strains of E. coli, and twenty-five
strains of K. pneumoniae were obtained as clinical isolates from different patients at
the Yale-New Haven Hospital. All strains were re-identified by standard bacterio-
logic methods in our research laboratory.
Antibiotics
Cefamandole lithium and tobramycin sulfate standard powders were supplied by
Eli Lilly and Company, Indianapolis, Indiana.
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Synergy Studies
For all studies, a checkerboard technique utilizing an automated serial microdilu-
tion system (Autotiter III, Canalco Co., Rockville, Md.) was employed as previously
reported [1]. All organisms were cultured in Mueller-Hinton Broth (MHB) and the
final inoculum in each study contained approximately 104 colony forming units/ml.
The minimal inhibitory concentration (MIC) was defined as the lowest concentra-
tion ofeach antibiotic either alone or in combination that prevented growth (detected
as turbidity on visual inspection of the wells on each microtitration plate) after 18
hours of incubation at 370C. The minimal bactericidal concentration (MBC) was
determined by transferring 0.05 ml of the contents from each well of the 18 hour
cultures to corresponding wells on a fresh microtitration plate containing plain
MHB. These subcultures were then read in the same manner as for MICs after 18
hours of incubation at 370C.
Studies of antibiotic combinations against each isolate were performed in tripli-
cate. The results were recorded as previously described [1,2] insofar as the combina-
tion was considered to have a synergistic action when a fourfold or greater reduction
of the MIC of both antibiotics occurred as compared to the MIC ofeach antibiotic
alone. A fourfold or greater reduction in the MIC of one antibiotic associated with a
twofold reduction of the other was considered to indicate partial synergy. The effect
of the combination was considered additive when a twofold reduction of the MIC
occurred for both antibiotics and indifferent when the MIC of one drug was un-
changed by the combination.
Final concentrations of cefamandole ranged from 0.015 to 128 ug/ml. Final
concentrations of tobramycin ranged from 0.012 to 0.75 ug/ml for studies with S.
aureus; from 0.05 to 3.0 ug/ml for studies with E. coli; and 0.19 to 12.0 ug/ml for
studies with K. pneumoniae.
RESULTS
The susceptibility ofthe various isolates to cefamandole and tobramycin are shown
in Tables 1 and 2 and are expressed as the cumulative percent of isolates killed by
each antibiotic at selected concentrations. The MIC ofcefamandole and tobramycin
when each drug was tested alone and incombination against each ofthe 25 isolates of
S. aureus studied are presented in Table 3. The ranges of MBC of each drug alone
and in combination against E. coli and K. pneumoniae are shown in Table 4.
Cefamandole
The minimal inhibitory concentration of cefamandole for Staphylococcus aureus
isolates ranged between 0.5 and 64 ug/ml. Escherichia coliisolates were inhibited in a
range between 0.5 and 16 ug/ml and Klebsiellapneumoniae isolates were inhibited in
concentrations ranging from 1.0 to 128 ug/ml. Ranges for MBCs were similar for the
three categories of isolates and were 0.5 to 64 ug/ml for S. aureus, 0.5 to 16 ug/ml for
E. coli, and 1.0 to 128 ug/ml for K. pneumoniae.
Tobramycin
Minimal inhibitory concentrations oftobramycin ranged from 0.05 to greater than
0.75 ug/ml for isolates of S. aureus although 84% of these isolates were killed by
0.375 ug/ml or less. The isolates of E. coli were inhibited by concentrations of0.375
to 1.50 ug/ml of tobramycin, and the K. pneumoniae isolates were inhibited in a
range between 0.19 to 0.75 ug/ml. The MBCs were in ranges similar to the MICs
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TABLE 1
Cumulative Percent of Isolates
Susceptible to Cefamandole
Cumulative percent of isolates
susceptible at MBC (ug/ml) of:
No. of
Organism Isolates
0.5 1.0 2.0 4.0 8.0 16.0 32.0 64.0 128
S. aureus 25 12 52 68 76 80 84 92 100 -
E. coli 24 17 29 46 79 96 100 - - -
K. pneumoniae 25 0 4 20 32 56 84 96 96 100
TABLE 2
Cumulative Percent of Isolates
Susceptible to Tobramycin
Cumulative percent of isolates
susceptible at MBC (ug/ml) of:
No. of
Organism Isolates
0.05 0.09 0.19 0.375 0.75 1.50 3.00
S. aureus 25 20 52 80 84 84 84 84
E. coli 24 0 0 0 4 75 96 100
K. pneumoniae 25 0 0 4 64 100 - -
although for individual isolates concentrations oftobramycin required for a bacteri-
cidal effect were sometimes two to four times the inhibitory concentrations.
Synergy Studies of Cefamandole-Tobramycin Combination
The combination demonstrated a synergistic or partially synergistic bactericidal
effect against many of the isolates tested. Synergism orpartial synergism between the
two antibiotics was demonstrated by appropriate reduction in minimal bactericidal
concentrations for 15 of the 25 S. aureus isolates (60%) when compared to MBCs for
each drug alone. Synergy or partial synergy in bactericidal effect was demonstrated
with 23 of 24 E. coli isolates examined (96%) and 19 of 25 K. pneumoniae isolates
(76%) examined. In many instances a greater than fourfold reduction in the MIC or
MBC of both antibiotics was observed when they were combined as compared with
their activity when used alone. In no case did we observe antagonism between the two
drugs.
DISCUSSION
In recent years a considerable effort by many investigators has been directed at
finding combinations ofantibiotics that are synergistic against pathogenic organisms.
Organisms responsible for bacterial endocarditis and gram-negative rod septicemia
have been the focus ofmuch ofthis investigation. An organism such as the enterococ-
cus which is difficult to eliminate from cardiac vegetations with single drug therapy is
more easily dealt with when appropriate antibiotic combinations are utilized. Gram-
negative sepsis is also a difficult infection to treat and successful therapy may depend
upon rapid elimination of the causative organisms from the blood stream. Gram-
negative rod endocarditis is associated with a high mortality even when the causative
organisms are sensitive to the antibiotics employed. Combination chemotherapy has
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TABLE 3
MICs of cefamandole and tobramycin alone and in combination-
action on 25 isolates of Staphylococcus aureus
Cefamandole Cefamandole + Tobramycin Tobramycin
Strain (ug/ml) (ug/ml) (ug/ml)
Synergy*
106 4.0 0.5 0.02 0.09
547 0.5 0.125 0.02 0.09
Partial Synergy**
137 2.0 0.06 0.09 0.19
147 0.5 0.125 0.05 0.09
268 0.5 0.125 0.02 0.05
343 1.0 0.125 0.02 0.05
376 1.0 0.125 0.02 0.05
402 2.0 0.25 0.02 0.05
403 1.0 0.25 0.02 0.05
1403 1.0 0.25 0.05 0.09
Partial Synergyt
70 1.0 0.5 0.02 0.09
83 2.0 1.0 0.02 0.19
109 2.0 1.0 0.02 0.19
155 8.0 4.0 0.05 0.19
295 0.5 0.25 0.02 0.09
1407 4.0 2.0 0.02 0.09
Additivett
864 1.0 0.5 0.05 0.09
947 1.0 0.5 0.05 0.09
1347 1.0 0.5 0.05 0.09
Indifference§
152 1.0 0.5 0.09 0.09
425 64.0 64.0 0.75 0.75
1348 0.5 0.5 0.05 0.05
Indeterminate§§
108 32.0 32.0 >0.75 >0.75
313 32.0 16.0 > 0.75 >0.75
533 32.0 32.0 > 0.75 > 0.75
*The MIC of each drug was at least four times as effective in combination as the MIC of that drug alone.
**The MIC of cefamandole was at least four times as effective in combination as it was alone while the MIC of
tobramycin was at least twice as effective in combination as it was alone.
tThe MIC of tobramycin was at least four times as effective in combination as it was alone, while the MIC of
cefamandole was at least twice as effective in combination as it was alone.
ttThe MICs of both drugs were twice as effective in combination as each was alone.
§The MIC of one drug was not changed by combining it with the other.
§§No tobramycin end point.
been widely advocated for this disease. In studies done in ourlaboratory withanimal
models of gram-negative sepsis, certain antibiotic combinations shown to be syner-
gistic in vitro decreased the number ofbacteria at the challenge site, reduced the level
of bacteremia and significantly improved survival in rats given an intraperitoneal
challenge of Pseudomonas aeruginosa when compared to controls treated with saline
or a single drug [1,2]. We have also observed this in a corresponding model ofCEFAMANDOLE-TOBRAMYCIN SYNERGY
TABLE 4
Range of MBCs of cefamandole and tobramycin alone and in combination-
action on 24 isolates of E. coli and 25 isolates of K. pneumoniae
No. of Range of MBCs Range of MBCs Range of MBCs
Isolates Cefamandole Cefamandole + Tobramycin Tobramycin
(ug/ml) (ug/ml) (ug/ml) (ug/ml)
E. coli
Synergy 12 1.00-16.00 0.25-2.00 0.05-0.375 0.375-1.50
Partial Synergy 11 0.50-8.00 0.06-2.00 0.19-0.75 0.75-3.00
Indifference 1 8.00 4.00 0.75 0.75
K. pneumoniae
Synergy 9 4.00-16.00 0.06-2.00 0.05-0.19 0.375-0.75
Partial Synergy 10 1.00-32.00 0.06-16.00 0.05-0.19 0.19-0.75
Addition 4 2.00-4.00 1.00-2.00 0.19 0.375
Indifference 2 8.00-128.00 8.00-128.00 0.375-0.75 0.375-0.75
Klebsiella sepsis in rats [12]. Recently, Lumish and Norden have repeated this work
in neutropenic rats challenged with P. aeruginosa and observed similar results [3].
These considerations have prompted our investigation of other potentially useful
antibiotic combinations.
The results ofthe present study utilizingcefamandole and tobramycin indicate that
this combination acts synergistically against the majority of K. pneumoniae and E.
coli, organisms frequently implicated in gram-negative rod septicemia. Furthermore,
this synergistic effect was observed at clinically achievable concentrations of these
antibiotics. While this study reports only in vitro data, our previous experience
suggests that this drug combination is likely to show promise in vivo.
Although synergy was more frequently demonstrated with the gram-negative
organisms studied, synergism was also observed against some Staphylococcus aureus
isolates. This is of interest since staphylococcal sepsis, especially when it is associated
with endocarditis, is a devastating illness and it is desirable to find effective anti-
staphylococcal regimens which carry less risk for patients allergic to penicillins.
Vancomycin, an effective antibiotic alternative to penicillins for the treatment of
staphylococcal endocarditis, is quite toxic, and a recent report records its failure to
eliminate S. aureus from the blood stream of a patient with endocarditis until it was
combined with methicillin and gentamicin [4]. Synergism against staphylococci has
been previously demonstrated with combinations ofpenicillins and aminoglycosides
both in vitro and in vivo. Sande and Courtney, using a rabbit model ofstaphylococ-
cal endocarditis showed that organisms were cleared more rapidly from cardiac
vegetations in animals who received a combination of nafcillin and gentamicin than
with nafcillin alone. Gentamicin was not effective alone [5]. Steigbigel and co-
workers examining the effect of several antibiotic combinations on mortality in mice
infected with staphylococci were able to demonstrate enhanced efficacy ofpenicillin-
aminoglycoside combinations as compared to single drug therapy, but no advantage
over single drug therapy was demonstrated with combinations of clindamycin and
gentamicin or erythromycin and gentamicin [6]. Watanakunakorn and Glotzbecker
examined the in vitro activity of several anti-staphylococcal antibiotics alone and in
combination with aminoglycosides and observed enhancement ofthe effect ofcephal-
othin and cefazolin when they were combined with various aminoglycosides includ-
ing tobramycin [7]. The in vitro synergy shown by our work with cefamandole and
tobramycin is encouraging since both drugs may be employed in some patients
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allergic to penicillins. Comparisons with other cephalosporin-aminoglycoside combi-
nations in animal models seems warranted.
An additional finding which emerged from our studies with Staphylococcus aureus
was our observation that several isolates were more resistant to cefamandole than has
been previously reported. Furthermore, no reduction of the MIC ofeither drug was
observed when the combination was tested with four of these relatively resistant
isolates. Bodey and Weaver observed that 100% of the S. aureus isolates they tested
were killed at concentrations of cefamandole at or below 0.78 ug/ml [8]. Of 56
isolates studied by Neu, none required more than 1.6 ug/ml for inhibition [9]. Several
of our 25 isolates of S. aureus had MICs greater than 2.0 ug/ml. (These results were
confirmed in another laboratory) [10]. Similar resistance to cephalosporins has been
observed with methicillin-resistant strains. This resistance does not appear to be
related to f -lactamase production but rather to an as yet unexplained intrinsic
resistance which extends to other cephalosporins [11].
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